https://news.trust.org/item/20210508133239-l4wau/#:~:text=NEW%20YORK%2C%20May%208%20(Reuters,two%20cybersecurity%20industry%20sources%20said.
Recap: Regulus Therapeutics Q2 Earnings
Shares of Regulus Therapeutics (NASDAQ:RGLS) fell in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share increased 65.22% year over year to ($0.08), which were in line with the estimate of ($0.08).
